Patients in Wales with a rare disease that causes epilepsy will be the first in the UK to get access to GW Pharma's cannabis-based medicine Epidyolex, after the drug was cleared for use by
The UK’s GW Pharma has insisted there will be no repeat of the controversy seen with cystic fibrosis drugs after NICE said “no” to regular NHS funding for its Epidyolex for rare forms of ch